English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

.. Objectives: In last decade, “treatment of chronic hepatitis-C revolved from interferon based therapy to most effective interferon free therapy with new direct antiviral drugs like Sofosbuvir and ribavirin” which is recommended for all genotypes of HCV infection. Treatment response in Chronic Hepatitis-C is affected both by viral and human factors. We conducted this study “to evaluate the effect of human factor like (IL28B-rs12979860 non-CC) genotyping in response to Sofosbuvir based dual therapy in Hepatitis-C Genotype-3a infection” in population of Khyber PukhtoonKhwa (KPK). Setting: This open labeled, multi-center study was conducted in Peshawar-Khyber PukhtoonKhwa (KPK). Period: March-2016 to August-2016. Method: Total of 70patients were enrolled. After doing “PCR for HCV-RNA-Viral level, ViralGenotyping and Human genotyping for IL-28B, patients were put on Sofosbuvir and ribavirin for 24-weeks”. Patients were assigned into two groups (1:1), “having 35 in each, including group-A as those having favorable CC (IL28Brs12979860-CC) genotyping and group-B as those having unfavorable non-CC (IL28B-rs12979860-non-CC) genotyping”. The primary end point was “Sustained Virological response12 (SVR12), which is HCV-RNA level<40IU/ml at 12-weeks after completion of therapy in these two groups”. Results: Among 70-patients, male-female ratio was 57.15% (n=40) and 42.85% (n=30) respectively. Each group has 35-cases. Rate of SVR12 was 88.57% (n=31/35) in group-A, 91.42% (n=32/35) in group-B, having P-value<05. Conclusion: This study confirm that “unlike interferon, unfavorable non-CC (IL28B-rs12979860non-CC) genotyping have no or minimal role in treatment response to Sofosbuvir in Hepatitis-C genotype-3a infections”.

the professional medical journal/the professional medical journal

HEPATITIS-C GENOTYPE-3A INFECTION; ROLE OF UNFAVORABLE (IL28B- RS12979860 NON-CC) GENOTYPING IN RESPONSE TO SOFOSBUVIR (SOF) AND RIBAVIRIN IN PATIENTS IN POPULATION OF KHYBER PUKHTOONKHWA (KPK)